Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/1/2025

NSAIDs and Aneurysm Risk: Cardiovascular Considerations

Increased Thrombotic Risk

  • The American Heart Association acknowledges that all NSAIDs carry a risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal 1
  • The risk of cardiovascular events increases with duration of NSAID use and is higher in patients with existing cardiovascular disease or risk factors, as noted by the American College of Cardiology 1, 2
  • NSAIDs can worsen congestive heart failure and increase blood pressure, according to the American Academy of Family Physicians 2
  • Diclofenac shows a particularly elevated cardiovascular risk with a relative risk of 1.63 for vascular events versus placebo, as reported by the American Heart Association 1

Bleeding Risk in High-Risk Patients

  • The American Academy of Family Physicians recommends that NSAIDs be avoided in patients with platelet defects or thrombocytopenia due to dangerous synergistic effects on bleeding risk 3
  • When combined with anticoagulants, NSAIDs increase gastrointestinal bleeding risk 3-6 fold, as noted by the American College of Gastroenterology 3, 4
  • Acetaminophen is the preferred analgesic for patients with thrombocytopenia, stroke history, or those requiring anticoagulation, according to the American Society of Hematology 5
  • Topical NSAIDs (diclofenac gel or patch) have minimal systemic absorption and may be used when oral NSAIDs are contraindicated, as suggested by the National Comprehensive Cancer Network 6

Clinical Algorithm for NSAID Use with Aneurysms

  • For patients with aneurysms requiring anticoagulation, the American College of Cardiology recommends avoiding oral NSAIDs entirely and using acetaminophen as first-line analgesic 5, 6
  • Consider topical NSAIDs if pain control is inadequate, as noted by the National Comprehensive Cancer Network 6, 5

Key Pitfalls to Avoid

  • The American Heart Association advises against assuming all NSAIDs are equivalent, as COX-2 selective agents have different cardiovascular and bleeding profiles than nonselective NSAIDs 1
  • Aspirin's antiplatelet effects last 8-12 days, requiring longer preoperative discontinuation than other NSAIDs, as reported by the American Academy of Family Physicians 2
  • Do not combine NSAIDs with anticoagulants without GI prophylaxis and close INR monitoring, as recommended by the American College of Gastroenterology 3, 4
  • The American Academy of Family Physicians recommends against using NSAIDs in patients with congestive heart failure or uncontrolled hypertension 7, 2

Etodolac and Bleeding Risk

Comparative Bleeding Risk Profile

  • Etodolac demonstrates superior GI safety compared to traditional NSAIDs, with lower gastrointestinal toxicity associated with its use, similar to ibuprofen and nabumetone 8
  • The American Gastroenterological Association recommends considering etodolac as an alternative to other NSAIDs due to its lower risk of gastrointestinal bleeding 8

Absolute Bleeding Risks

  • History of peptic ulcer disease or gastrointestinal bleeding represents the most significant risk factor for GI events, with odds ratios as high as 13.5 8

High-Risk Populations Requiring Extreme Caution

  • Advanced age (≥60 years) should be considered before NSAID administration to prevent upper gastrointestinal tract bleeding and perforation, with the American College of Gastroenterology recommending caution in this population 9
  • The National Comprehensive Cancer Network recommends avoiding oral NSAIDs, including etodolac, in patients on anticoagulation therapy due to increased bleeding risk 9

Additional Risk Factors

  • Concurrent use of corticosteroids increases gastrointestinal bleeding risk, with the American College of Rheumatology recommending caution when combining these medications 9
  • Concomitant use of NSAID with low-dose aspirin may increase the risk of gastrointestinal bleeding, according to the American Heart Association 9

Risk Mitigation Strategies

  • The American College of Gastroenterology recommends considering misoprostol or proton pump inhibitors as prophylaxis for NSAID peptic ulceration in high-risk patients 9
  • The National Comprehensive Cancer Network suggests using topical NSAIDs, such as diclofenac gel or patch, in patients requiring anticoagulation as an alternative to oral NSAIDs 9

Monitoring Requirements

  • The American College of Gastroenterology recommends obtaining baseline CBC and fecal occult blood before initiating etodolac, and repeating these tests every 3 months to ensure lack of toxicity 10
  • Patients on long-term treatment should have hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia, according to the National Comprehensive Cancer Network 10

REFERENCES

2

nsaid prescribing precautions. [LINK]

American family physician, 2009

3

nsaid prescribing precautions. [LINK]

American family physician, 2009

4

nsaid prescribing precautions. [LINK]

American family physician, 2009

5

NSAIDs and Bleeding Risk in Thrombocytopenia and Stroke [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6

adult cancer pain, version 3.2019, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

7

nsaid prescribing precautions. [LINK]

American family physician, 2009

9

adult cancer pain, version 3.2019, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

10

adult cancer pain. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010